# US 7,745,222 B2 · Amyloid binding assays

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,222 B2
- Document ID: US7745222B2
- Status: Granted
- Kind: B2
- Application number: 11/580,493
- Filed: 2006-10-13
- Published: 2008-11-06
- Granted: 2010-06-29
- Earliest claimed: 2006-10-13
- Assignees: General Electric Company
- Inventors: Kenneth Michael Fish; Cristina Tan Hehir; Michael Christopher Montalto; Eric Dustin Agdeppa
- Web page: https://patentgrep.com/patent/US7745222B2

## CPC

- G01N 33/5088: {of vertebrates}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2333/4709: Amyloid plaque core protein
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are amyloid-binding assays that simulate in situ brain conditions by combining binders with various A-beta species on mammalian brain tissue. In general the amyloid-binding assays comprise the steps of (a) contacting a mammalian brain tissue sample with at least one A-beta species; (b) applying a putative binder to the brain tissue sample; and (c) determining whether the putative binder binds to the A-beta species.

## Claims

### Claim 1

A method of identifying a putative binder to bind an A-beta-derived polypeptide having SEQ ID: 1 comprising the steps of:
(a) contacting a mammalian brain tissue sample with at least one A-beta-derived polypeptide having SEQ ID: 1;
(b) applying a putative binder to the brain tissue sample; and
(c) determining whether the putative binder binds to the A-beta-derived polypeptide having SEQ ID: 1.

### Claim 2 (depends on 1)

The method of claim 1, wherein the contacting step includes introducing the at least one A-beta-derived polypeptide having SEQ ID: 1 into an intact mammalian brain before the applying step.

### Claim 3 (depends on 1)

The method of claim 1, wherein the at least one A-beta-derived polypeptide having SEQ ID: 1 is introduced into a mammalian brain by intracranial injection or intravascular injection.

### Claim 4 (depends on 1)

The method of claim 1, further comprising the step of isolating a brain tissue sample from an intact brain prior to the applying step.

### Claim 5 (depends on 1)

The method of claim 1, further comprising the step of creating a tissue section of about 10 microns to about 30 microns thick.

### Claim 6 (depends on 1)

The method of claim 1, further comprising the step of applying a preserving agent to the brain tissue sample.

### Claim 7 (depends on 1)

The method of claim 1, further comprising one or more washing steps following either or both the contacting and applying steps.

### Claim 8 (depends on 1)

The method of claim 1, wherein the A-beta-derived polypeptide having SEQ ID: 1 substantially comprises a naturally occurring or synthetic monomers or multimers of A-beta.

### Claim 9 (depends on 1)

The method of claim 1, wherein the amount of the A-beta-derived polypeptide having SEQ ID: 1 applied to the brain tissue sample is a concentration of about 0.1 pM to about 0.1 nM.

### Claim 10 (depends on 1)

The method of claim 1, wherein the A-beta-derived polypeptide having SEQ ID: 1 spies is selected from soluble or insoluble A-beta.

### Claim 11 (depends on 1)

The method of claim 1, wherein the binder comprises an antibody or a functional antibody fragment.

### Claim 12 (depends on 1)

The method of claim 1, further comprising the step of applying at least one signal generator capable of binding to the binder to the brain tissue prior to the observing step.

### Claim 13 (depends on 1)

The method of claim 1, wherein the observing step comprises observing the binding using fluorescence microscopy or radiographic imaging.